• Dry Cracked Skin
  • Impetigo
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Onset acquires rights to acne med Clindagel

Article

The acne medication Clindagel (clindamycin phosphate 1 percent) topical gel is now owned by Onset Dermatologics, according to a news release.

 

The acne medication Clindagel (clindamycin phosphate 1 percent) topical gel is now owned by Onset Dermatologics, according to a news release.

Onset Dermatologics, a PreCision Dermatology company, acquired the prescription medication from Galderma Laboratories, the company stated.

“I am delighted that Onset will be promoting and bringing Clindagel back to my practice,” Jerald L. Sklar, M.D., of Dallas Associated Dermatologists in Dallas, said in the release. “As dermatologists, we choose to prescribe agents with high patient acceptability for chronic conditions such as acne.”

Clindagel is applied once daily and is the only such topical formulation of clindamycin phosphate that is approved by the Food and Drug Administration.

“My acne patients have always appreciated the ease of once daily dosing and the pleasant water base vehicle of Clindagel,” Dr. Sklar said in the release.

Clindagel will be promoted by Onset in December, and Clindagel 75 mL will be available for order through Galderma Laboratories until mid-December.

 

Related Videos
© 2024 MJH Life Sciences

All rights reserved.